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Abstract
Background: Although targeted interventions in India require all high-risk groups, including injecting drug users
(IDUs), to test for HIV every 6 months, testing uptake among IDUs remains far from universal. Our study estimates
the proportion of IDUs who have taken an HIV test and identifies the factors associated with HIV testing uptake in
Nagaland and Manipur, two high HIV prevalence states in India where the epidemic is driven by injecting drug use.
Methods: Data are drawn from the cross-sectional Integrated Behavioural and Biological Assessment (2009) of
1650 male IDUs from two districts each of Manipur and Nagaland. Participants were recruited using respondent-driven
sampling (RDS). Descriptive data were analysed using RDSAT 7.1. Multivariate logistic regression analysis was
undertaken using STATA 11 to examine the association between HIV testing and socio-demographic, behavioural and
programme exposure variables.
Results: One third of IDUs reported prior HIV testing, of whom 8 % had tested HIV-positive. Among those without
prior testing, 6.2 % tested HIV-positive in the current survey. IDUs aged 25–34 years (adjusted odds ratio (OR) = 1.41;
95 % confidence interval (CI) = 1.03–1.93), married (Adjusted OR = 1.56; 95 % CI = 1.15–2.12), had a paid sexual partner
(Adjusted OR = 1.64; 95 % CI = 1.24–2.18), injected drugs for more than 36 months (Adjusted OR = 1.38; 95 % CI = 1.06–
1.81), injected frequently (Adjusted OR = 1.49; 95 % CI = 1.12–1.98) and had high-risk perception (Adjusted OR = 1.68;
95 % CI = 1.32–2.14) were more likely than others to test for HIV. Compared to those with no programme exposure,
IDUs who received counselling, or counselling and needle/syringe services, were more likely to test for HIV.
Conclusions: HIV testing uptake among IDUs is low in Manipur and Nagaland, and a critical group of HIV-positive
IDUs who have never tested for HIV are being missed by current programmes. This study identifies key
sub-groups—including early initiators, short duration and less frequent injectors, perceived to be at low
risk—for promoting HIV testing. Providing needles/syringes alone is not adequate to increase HIV testing;
additionally, interventions must provide counselling services to inform all IDUs about HIV testing benefits,
facilitate visits to testing centres and link those testing positive to timely treatment and care.
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Background
Injection drug users (IDUs) are a group at high risk of
acquiring and transmitting HIV due to unsafe injection
and sexual practices [1–3]. Although IDUs are a priority
group for targeted interventions in India where the epi-
demic is concentrated among high-risk groups, rising
HIV prevalence among IDUs continues to be a concern.
Nationally, HIV prevalence (2014–2015) is higher
among IDUs (9.9 %) than female sex workers (FSWs)
and men who have sex with men (MSM) (2.2 and 4.3 %
respectively), and while the epidemic has been stabilising
among FSWs and MSM, HIV prevalence among IDUs
has been rising [4]. Moreover, new IDU-driven epi-
demics are emerging in India, with several states/regions
reporting high HIV prevalence (>10 %) among IDUs [4].
HIV testing is a cost-effective strategy for the reduc-
tion of HIV risk and transmission [5] and provides an
entry point for prevention, treatment and care. Early
HIV diagnosis can lead to timely initiation of treatment
[6–8] and knowledge of sero-positive status through
testing can lead to the adoption of safer injection and
sexual behaviours [2, 9–13]. Additionally, HIV testing
provides a critical opportunity to counsel clients on risk
reduction. HIV testing is a priority of the Indian govern-
ment, and targeted interventions require all high-risk
groups, including IDUs, to test for HIV once every
6 months [14, 15]. With the aim of increasing HIV test-
ing accessibility and availability, the Indian government
has scaled up voluntary counselling and testing (VCT)
services for HIV across the country [15].
In India, the majority of IDUs are from the states of
Manipur and Nagaland, two high HIV prevalence states
where the HIV epidemic is primarily driven by injection
drug use [6] [5]. The vast majority of IDUs in Manipur
and Nagaland are male [16], and approximately 2 % of
the adult population in these states engage in injecting
drugs, mainly heroin and spasmo-proxyvon (a synthetic
opioid analgesic) [17]. These mountainous states are lo-
cated on India’s north-eastern border with Myanmar,
where illicit drugs are readily accessible [18]. These
states have primarily rural populations and are charac-
terised by ethnic and linguistic diversity; poor road and
health service infrastructure; ethnic conflict; armed in-
surgency; poverty; and unemployment [16]. These two
states have historically been priority states for targeted
IDU interventions under the Indian government’s Na-
tional AIDS Control Programme (NACP). Additionally,
Avahan, the India AIDS initiative has been implementing
a scaled up comprehensive harm reduction programme
(2004–2014) for IDUs in these states. Services include
distribution of sterile needles and syringes, counselling,
condom distribution, sexually transmitted infection
(STI) treatment, abscess management, opioid substitu-
tion therapy (OST), VCT referrals and linkages to
detoxification/rehabilitation services [19, 16]. Although
IDUs have been the focus of targeted services in these
two states, infection rates among IDUs continue to be
high (12.1 % in Manipur and 3.2 % in Nagaland, 2014–
2015 estimates) [4]. Manipur and Nagaland were among
the states that recorded the highest HIV prevalence
(0.64 and 0.88 %, respectively; 2012–2013 estimates)
among antenatal clinic attendees [20], and adult HIV
prevalence in Manipur and Nagaland (1.22 and 0.73 %;
2011 estimates) was higher than the national prevalence
rate (0.27 %) [21].
Although prevention interventions in India have fo-
cused on saturating HIV testing among high-risk groups,
including IDUs, testing uptake among IDUs remains far
from universal [4]. As a result, many IDUs who are HIV
infected are unaware of their status and may transmit
the virus to others. Despite the critical importance of
IDUs to HIV prevention and care efforts, limited infor-
mation is available on the characteristics of IDUs under-
going HIV testing in India. To address this gap, our
study estimates the proportion of IDUs who have taken
an HIV test and identifies the factors associated with
HIV testing uptake in Nagaland and Manipur, two high
HIV prevalence states in India where the epidemic is
driven by injecting drug use. Our findings will provide
valuable inputs for future programmes aimed at increas-
ing HIV testing uptake and reducing HIV transmission,
among IDUs in India.
Methods
Study design
Data for this study are drawn from the 2009 Integrated
Behavioural and Biological Assessment (IBBA), a cross-
sectional survey that used an interviewer-administered
questionnaire and the collection of blood samples to test
for HIV. The survey was conducted in April–June among
male IDUs in two districts of Manipur (Churachandpur
and Bishnupur) and in May–July in two districts of
Nagaland (Phek and Wokha). Approval for the study
protocol was obtained from the Government of India’s
Health Ministry Screening Committee and the ethical
review boards of participating institutions. A compre-
hensive consent process was adopted: respondents
were informed about all aspects of the survey, follow-
ing which verbal consent was obtained individually
for the behavioural and biological component. Partici-
pation was voluntary with the option to withdraw at
any time. Questionnaires and biological testing were
anonymously linked so the results could not be traced
back to the respondent.
Sampling
Participants were recruited using respondent-driven
sampling (RDS). RDS is a validated probability sampling
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method based on conventional sampling used to re-
cruit hidden populations such as sex workers and
IDUs [22, 23]. For this study, four to eight seeds from
the target population who met the study eligibility
criteria were purposively selected to reflect the diver-
sity of demographic characteristics. Each seed partici-
pant was given three uniquely coded coupons to refer
three eligible IDU peers from his network for recruitment
into the study. These recruits, in turn, were provided three
coupons each to recruit three additional IDUs for the next
wave. This peer-to-peer recruitment process continued
until the desired sample size was achieved. All participants
were provided a primary incentive (INR 70; 1 USD =
approximately INR 65) for participating in the study and a
secondary incentive (INR 30) for recruiting an eligible
peer into the study [24].
In this study, a sample size of 400 was estimated for
each survey district, which allowed for detection of an
absolute difference of 15 % or more from the assumed
value of 50 % with 95 % confidence (5 % probability of
type I error) and 90 % power (10 % probability of type II
error), for indicators such as use of clean needles. A
design effect of 1.5 was applied. Methodological details
of the study have been described elsewhere [14].
Data collection
Eligible individuals were male, aged 18 years or older,
who had injected drugs for non-medical purposes at
least once in the last 6 months. Face-to-face inter-
views were conducted by trained investigators in the
local language, using a structured questionnaire that
included questions on socio-demographic characteris-
tics, injecting behaviour, sexual behaviour, exposure to
interventions and prior HIV testing. Additionally, re-
spondents provided finger prick blood samples for
HIV testing [14].
Statistical analysis
Descriptive data were analysed using RDSAT 7.1 to gen-
erate adjusted proportion estimates with 95 % confi-
dence intervals. Multivariate logistic regression analysis
was undertaken using STATA 11 to examine the associ-
ation between HIV testing prior to the survey and the
explanatory variables (age, marital status, occupation,
paid sexual partner, regular sexual partner, duration of
injection use, frequency of injecting drugs, sharing nee-
dles/syringes, knowledge of STI, risk perception and
programme exposure). Results are presented for the
overall sample as the site-specific associations were ob-
served to be generally similar. Individualised weights
were generated for the dependent variable (i.e. ever
tested for HIV) using RDSAT analysis and applied to the
logistic regression analysis in STATA.
Measures
The dependent measure considered in this study was
ever tested for HIV (yes/no). Current HIV status was de-
termined based on the laboratory test result, and respon-
dents were considered HIV-positive if their blood
samples tested positive on the Microlisa test and con-
firmed by the Genedia HIV ½ ELISA 3.0 test.
Socio-demographic characteristics included age, oc-
cupation and marital status. Age was measured as a
continuous variable and grouped into three categories
(18–24; 25–34; 35 years and above). Marital status
was categorised as being never married or ever mar-
ried, and employment status recorded as a response
to a direct question and grouped into three categor-
ies: unemployed, student and employed.
The sexual behaviours considered in the study include
had a regular sex partner ever (yes/no) and had a paid
sex partner ever (yes/no). The injection practices consid-
ered in this study include duration of injection use, fre-
quency of injection in the past 1 month and sharing
needles/syringes (yes/no) in the past 1 year. Duration of
injection use was measured as a continuous variable and
categorised into two groups (injecting drugs for
36 months or less/injecting drugs for more than
36 months). Frequency of injection use was dichoto-
mised as less frequent (defined as injecting three times
or less in the past month) or more frequent (defined as
injecting more than three times in the past month).
Other key independent variables considered include
knowledge of STI (Have you ever heard of diseases that
can be transmitted through sexual intercourse (also
known as STI)? (yes/no)); risk perception (Do you feel
that you are at risk for becoming infected with HIV/
AIDS?) (high risk/low risk)); and programme exposure.
Participants were divided into three groups to assess
programme exposure in the past 6 months: those who
received no programme services were coded as 1 (no
exposure); those who received only needle and syringe
services were coded as 2; and those who received only
counselling services from a peer educator/outreach
worker or both counselling from a peer educator/out-




A total of 1650 IDUs (Manipur, N = 821; Nagaland, N =
829) were recruited (Table 1). State-wise differences
were noted in age distribution and marital status. Over-
all, the majority were in the age group 25–34 years;
nearly half (46 %) were employed and three-fifths (60 %)
were never married. Most respondents (59 %) had a
regular sexual partner and one fifth (20 %) had a paid
sexual partner. Differences by state were observed with
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Table 1 Profile of IDUs, Manipur and Nagaland and overall
Characteristics Manipur % (95 % CI) Nagaland % (95 % CI) Overall % (95 % CI)
Age (years)
18–24 22.6 (18.5–26.7) 44.6 (39.3–49.4) 33.2 (29.7–36.5)
25–34 59.9 (55.4–64.4) 40.9 (36.1–46.0) 50.6 (47.2–54.0)
35+ 17.5 (14.2–21.1) 14.5 (11.2–18.2) 16.2(13.9–18.7)
Occupation
Unemployed 42.3 (37.8–47.2) 49.7 (4.43–5.50) 46.2 (4.26–4.97)
Student 3.9 (2.0–6.4) 13.3 (9.9–17.7) 8.4 (6.5–10.7)
Employed 53.7 (48.8–58.3) 37.0 (31.9–41.6) 45.5 (42.1–48.8)
Marital status
Never married 53.7 (48.8–58.4) 65.2 (60.4–69.4) 59.6 (56.2–62.9)
Ever married 46.3 (41.6–51.2) 34.8 (30.6–39.6) 40.4 (37.1–43.8)
Sexual practices
Had a regular sexual partner evera
No 55.8 (51.2–60. 2) 27.0 (22. 6–31. 8) 41.5 (38. 0–44.9)
Yes 44.2 (39.8–48.8) 73.0 (68.2–77.4) 58.5 (55.1–62.0)
Had a paid sexual partner everb
No 69.1 (64.8–73.3) 90.8 (87.8–93.2) 80.2 (77.5–82.9)
Yes 30.9 (26.7–35.2) 9.2 (6.8–12.2) 19.8 (17.1–22.5)
Injecting practices
Duration of injecting drug use (months)
<=36 34.9 (30.3–40.2) 69.6 (65.0–73.6) 51.9 (48.5–55.5)
>36 65.1 (59.8–69.7) 30.4 (26.4–35.0) 48.1 (44.5–51.5)
Frequency of injecting drugs in past 1 monthc
Less frequent 25.1 (20.5–30.2) 44.3 (39.4–49.1) 34.1 (30.6–37.3)
More frequent 74.9 (69.8–79.5) 55.7 (50.9–76.0) 65.9 (6.27–6.94)
Shared needles/syringes in past 1 year
No 43.4 (38.3–48.2) 39.6 (35.2–44.6) 41.3 (38.0–44.7)
Yes 56.6 (51.8–61.7) 60.4 (55.4–64.8) 58.7 (55.3–62.0)
Knowledge of STI
Not aware 22.7 (18.4–26.8) 31.7 (26.6–36.5) 26.8 (23.7–30.3)
Aware 77.3 (73.2–81.6) 68.3 (63.5–73.4) 73.2(69.7–76.3)
Risk perception
Low risk 50.3 (45.5–54.9) 68.7 (64.3–73.2) 59.7 (56.6–63.2)
High risk 49.7 (45.1–54.5) 31.3 (26.8–35.7) 40.3 (36.8–43.4)
Ever taken an HIV test prior to survey
No 52.4 (47.6–56.7) 83.0 (79.4–85.9) 67.4 (64.5–70.5)
Yes 47.6 (43.3–52.4) 17.0 (14.1–20.6) 32.6 (29.5–35.6)
HIV status
HIV-negative 72.3 (67.9–76.5) 98.5 (97.3–99.5) 84.4 (80.8–86.4)
HIV-positive 27.7 (23.5–32.1) 1.5 (0.5–2.7) 15.6 (13.6–19.2)
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regard to sexual partners: a higher proportion of IDUs
from Nagaland than Manipur reported ever having a
regular sexual partner whereas a higher proportion of
IDUs from Manipur as compared to Nagaland reported
ever having had a paid sexual partner.
Two thirds of IDUs (66 %) reported injecting fre-
quently (more than three times in the past month), and
almost half (48 %) reported long-term injecting use
(more than 36 months). Significant differences were ob-
served across states in terms of duration of injecting
drug use, with a higher proportion of IDUs in Manipur
as compared to Nagaland injecting for more than
36 months. More than half (59 %) of the IDUs had
shared needles/syringes in the past 1 year. Almost three
fourths (73 %) were aware of STIs, and two fifths per-
ceived themselves to be at high HIV risk.
Around one third (34 %) of IDUs had no programme
exposure in the past 6 months; while two fifths (20 %)
had received only needles and syringes from the
programme, almost half (46 %) had received only coun-
selling services or counselling and needle/syringe ser-
vices from the programme.
One third (33 %) of IDUs reported ever having under-
gone a prior HIV test; of these, 8 % had tested HIV-
positive. Significant differences were noted across the
states, with a higher proportion of IDUs from Manipur
than Nagaland ever having taken an HIV test. Of those
who reported prior testing, a higher proportion of IDUs
from Manipur (28 %) than Nagaland (2 %) had tested
HIV-positive. Among those who had not undergone
prior HIV testing, 6.2 % tested positive in the current
survey (not shown in tabular form).
Factors associated with prior HIV testing
As seen in Table 2, IDUs in the age group 25–34 years
(adjusted odds ratio (OR) = 1.41; 95 % confidence interval
(CI) = 1.03–1.93)) and who were ever married (Adjusted
OR = 1.56; 95 % CI = 1.15–2.12) were more likely than
their counterparts to test for HIV. IDUs who had a paid
sexual partner (Adjusted OR = 1.64; 95 % CI = 1.24–2.18)
and those who had injected drugs for more than
36 months were more likely than others to test for HIV
(Adjusted OR = 1.38; 95 % CI = 1.06–1.81). Similarly, IDUs
who injected more frequently (Adjusted OR = 1.49; 95 %
CI = 1.12–1.98) had a higher likelihood of testing for HIV
compared to those who injected less frequently. IDUs who
had high-risk perception (Adjusted OR = 1.68; 95 % CI =
1.32–2.14) were more likely to test for HIV compared to
their counterparts. Additionally, compared to those with
no programme exposure, IDUs who reported either re-
ceiving only peer counselling, or both peer counselling
and needle/syringe services from the programme in the
past 6 months, were more likely to test for HIV.
Discussion
Despite the scale up of VCT services in India, our study
shows that HIV testing rates among IDUs are low in
Manipur and Nagaland, where the HIV epidemic is
driven by injection drug use. Although these states have
been prioritised for IDU-focused HIV prevention pro-
grammes, just one third of male IDUs in these settings
had ever tested for HIV despite 66 % having accessed
programme services; these rates are far below the na-
tional goal of saturating HIV testing among high-risk
groups in India [15]. Similar low testing rates among
IDUs have been reported in other studies in India as well
[25–27].
Under targeted interventions, all high-risk groups, in-
cluding IDUs, must test for HIV every 6 months; how-
ever, recent estimates (2014–2015) indicate that testing
rates remains far below the desired level. One third of
IDUs nationally have never tested for HIV, and in some
high HIV prevalence regions/states such as Bihar and
Uttar Pradesh (HIV prevalence among IDUs >27 %), less
than one third had taken an HIV test ever [4]. Although
nationally ever-testing rates among IDUs have increased
from those reported in our study, perhaps as a result of
focused interventions for IDUs under NACP, the contin-
ued testing gap is a challenge for HIV prevention efforts,
particularly in the context of IDUs’ high-risk behaviours,
rising HIV prevalence in this group and emerging IDU-
driven epidemics in several states/regions [4]. Notably,
in India, nationally, HIV ever-testing rates are lowest
among IDUs as compared to MSM (78 %) and FSWs
Table 1 Profile of IDUs, Manipur and Nagaland and overall (Continued)
Programme exposure (last 6 months)
No exposure 18.7 (14.4–23.4) 55.0 (48.7–60.8) 33.6 (29.1–36.8)
Received only needle syringe services 27.3 (23.9–31.6) 12.2 (9.3–15.3) 20.2 (17.5–22.8)
Received only counselling services or counselling
and needle/syringe services
54.0 (48.8–58.4) 32.8 (27.9–38.4) 46.2 (43.4–50.7)
CI confidence interval, STI sexually transmitted infection
aRegular sexual partner: main steady partner/spouse with whom IDUs had sex ever
bPaid sexual partner: women with whom IDUs had sex ever in exchange for cash/drugs/kind ever
cLess frequent includes those who injected drugs three times or less in the past 1 month; more frequent includes those who injected drugs more than three
times in the past 1 month
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(84 %) [4]. Increased prevention efforts for IDUs, includ-
ing regular VCT uptake by all IDUs across all states in
the country is crucial, given the potential for HIV trans-
mission in this high-risk group.
State-level differences in HIV testing are observed; far
fewer IDUs in Nagaland than Manipur reported ever
taking an HIV test, which may in part be explained by
lower self-perceived HIV risk in Nagaland, Nagaland’s
relatively more difficult terrain, hindering access to test-
ing facilities [28], and Manipur’s historically higher HIV
prevalence among IDUs, resulting in a more effective
testing response [27]. Despite these differences in testing
rates, IDUs in both states have high HIV prevalence and
should continue to be the focus of HIV prevention
programmes.
Of concern is the finding that among IDUs without
prior HIV testing, around 6 % tested HIV-positive in the
current study. These IDUs are most at risk, as they are
unaware of their sero-status and, therefore, may not be
linked to treatment and may continue to transmit HIV
infection through their risk behaviours [2, 26]. As early
detection is essential to provide timely care and treat-
ment, and prevent further HIV transmission, pro-
grammes must ensure that all IDUs test regularly for
HIV, promote the adoption of risk reduction behaviours
and link HIV-positive IDUs to timely care and
treatment.
Our study identifies several sub-groups of drug injec-
tors who are less likely to test for HIV and hence at high
risk of acquiring and transmitting HIV; these critical
groups should be the focus of intervention programmes
to promote HIV testing. While less frequent injectors
and recent injectors are considered to be at lower risk
[3, 26, 29], our findings support published studies docu-
menting the HIV vulnerability of new and recent initia-
tors and less frequent injectors [30–33] as they are less
likely than their counterparts to take an HIV test. Cor-
roborating these findings, a post hoc analysis indicates
that around two thirds of IDUs in this study who shared
injection equipment are short-term injectors and less
frequent injectors.
While studies have documented that IDUs’ risky injection
and sexual behaviours elevate the risk of HIV transmission
to their sexual partners [3, 31, 34], our study reports that
IDUs with paid sex partners, a particularly high-risk group,
are more likely than others to test for HIV, suggesting that
targeted interventions have been effective in promoting
protective behaviours. At the same time, the finding that
most IDU respondents had a regular sexual partner, but
the odds of testing were not higher in this group, suggests
that this sub-group of IDUs and their sexual partners are at
risk of acquiring and transmitting HIV [1, 3, 25]. Our study
also highlights the vulnerability of unmarried IDUs [3] as
they are less likely than married IDUs to test for
Table 2 Factors associated with HIV testing among IDUs,
Manipur and Nagaland, overall
Variables % (N= 652) Overall adjusted
OR (95 % CI)
Age (years)
18–24 26.75 (126) Ref
25–34 45.13 (408) 1.41 (1.03–1.93)
35+ 42.91 (118) 1.07 (0.69–1.66)
Occupation
Unemployed 36.53 (255) Ref
Student 32.06 (42) 1.27 (0.80–2.02)
Employed 43.24 (355) 1.23 (0.96–1.59)
Marital status
Never married 34.18 (324) Ref
Ever married 46.72 (328) 1.56 (1.15–2.12)
Had a regular sexual partner evera
No 39.45 (258) Ref
Yes 39.56 (394) 0.96 (0.74–1.25)
Had a paid sexual partner everb
No 35.49 (456) Ref
Yes 53.70 (196) 1.64 (1.24–2.18)
Duration of injecting drug use (months)
<=36 26.68 (203) Ref
>36 50.51 (449) 1.38 (1.06–1.81)
Frequency of injecting drugs in past monthc
Less frequent 25.15 (127) Ref
More frequent 45.85 (525) 1.49 (1.12–1.98)
Shared needles/syringes in past year
No 38.51 (223) Ref
Yes 40.06 (429) 1.08 (0.84–1.38)
Knowledge of STI
Not aware 18.13 (68) Ref
Aware 45.80 (584) 1.39 (0.10–1.93)
Risk perception
Low risk 28.68 (255) Ref
High risk 52.17 (397) 1.68 (1.32–2.14)
Programme exposure (last 6 months)
No exposure 12.47 (61) Ref
Received only needle/syringe services 33.64 (110) 1.05 (0.48–2.32)
Received only counselling services or
counselling and needle/syringe services
57.67 (481) 2.44 (1.06–5.60)
Model controlled for the variables considered in the analysis
OR odds ratio, CI confidence interval, STI sexually transmitted infection
aRegular sexual partner: main steady partner/spouse with whom IDUs had
sex ever
bPaid sexual partner: women with whom IDUs had sex ever in exchange for
cash/drugs/kind ever
cLess frequent includes those who injected drugs three times or less in the
past 1 month; more frequent includes those who injected drugs more than
three times in the past 1 month
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HIV. As HIV counselling and testing promote safe
sex behaviours among IDU populations [1, 35], efforts
are needed to encourage all IDUs who are sexually
active to test regularly for HIV, to prevent the onward
transmission of infection to their sexual partners.
Consistent with other studies, our study shows that
high perceived risk of HIV infection is a significant pre-
dictor for HIV testing [36, 37]. Given the evidence that
approximately three fifths of IDUs in our study per-
ceived they were at low HIV risk, despite their risky be-
haviours, efforts to increase HIV testing among IDUs
must strengthen strategies to build awareness of per-
sonal risk.
While our study findings indicate that programme ex-
posure is positively associated with HIV testing, not all
IDUs reported recent contact with the programme. Not-
ably, IDUs who received counselling were far more likely
to test for HIV than other IDUs—those without recent
programme contact or those who received only clean in-
jection equipment from the programme. These findings
suggest that the utilisation of needle and syringe services
alone does not necessarily translate into testing uptake
and must be supported with focused risk reduction infor-
mation for sustained behaviour change [28] to maximise
HIV testing.
Prior research among high-risk groups has docu-
mented that multiple factors influence the decision to
undergo HIV testing. Individual-level barriers, including
anxiety about a positive test result, lack of awareness
about antiretroviral treatment (ART), low HIV risk per-
ception and fear of being seen accessing HIV services, as
well as structural barriers, such as HIV-related stigma,
criminalisation of drug use, quality of care (discrimination
by health providers) and accessibility issues (inconvenient
testing hours, travel cost, long registration process and
long waiting time to receive test result) [38, 39] need to be
addressed if HIV testing uptake among IDUs is to be
maximised.
Peer-led outreach can expand programme coverage
among marginalised groups and address HIV testing
barriers. Peers are often the initial source of information
on HIV, including testing benefits and available testing
and treatment facilities [40–43]; they can reach hidden
IDUs and can be trusted to keep HIV status confidential
[38, 39]. Moreover, peers can accompany IDUs to health
testing facilities if necessary and sensitise health workers
to IDUs’ special needs. Prevention programmes must in-
vest in strengthening existing peer networks to increase
HIV testing uptake. Peers should be given well-defined
targets, including for referrals to VCT centres, to maxi-
mise testing.
The study findings also point to the need for pro-
grammes to strategically focus on counselling, in
addition to providing needle and syringe services, to
promote HIV testing. Counselling sessions must build
awareness of the benefits of regular HIV screening and
early HIV diagnosis and treatment; promote awareness of
the efficacy of ART and the availability of government-
supported treatment services; and raise the perception of
personal risk for HIV. Repeated and time-intensive peer
counselling is more effective than single sessions in re-
inforcing behaviour change [41] and should be adopted by
the programme.
Additionally, integrating HIV testing at the primary
healthcare level is a cost-effective strategy to increase
HIV screening, provide linkages to ART centres and
reduce HIV testing stigma [8, 44]. Voluntary drug
treatment facilities are well-suited to promoting HIV
testing; they provide IDUs an important point of con-
tact with the health system and can engage individ-
uals in HIV testing by linking them to testing centres;
moreover, drug users who come for treatment may be
ready to initiate behaviour change [39, 45, 46]; the
OST programme for IDUs, which is being scaled up
in India [47], could play an important role in promot-
ing testing coverage across the country. Mobile HIV
testing clinics could increase testing accessibility in
remote areas [18]. New and short-term injectors, who
are less likely to test for HIV, can be reached by
enlisting young peer educators and organising social
activities to attract them to testing services [18].
Youth clubs, which have wide reach in the country,
could be engaged to reach young IDUs and create
awareness about injection risk behaviours and pro-
mote HIV testing. These pilots could be scaled up if
successful.
While this study provides important insights to pro-
mote HIV testing among IDUs to prevent further
HIV transmission in this high-risk group, the findings
must be interpreted in light of certain limitations.
First, the study is based on self-reported risk behav-
iours, which may be subject to social desirability bias,
and as a result, socially unacceptable behaviours may
have been underreported. The use of trained field
staff may have increased participants’ level of comfort
at the time of interview and reduced underreporting.
We considered only male IDU respondents for the
current analysis, and the study may have missed a
group of female IDUs who have not tested for HIV.
Anecdotal evidence suggests that non-injecting drug
use is more common among female drug users [26],
and given the evidence that the vast majority of IDUs
in India are male, we limited the current analysis to
male IDUs only. Further, as injecting drug use charac-
teristics vary across states in India, our results may
not be generalisable to IDUs in other states and set-
tings. However, these limitations do not compromise
the internal validity of the data.
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Conclusions
HIV testing uptake is low among IDUs in Manipur and
Nagaland, India. A critical group of IDUs—those who
are HIV-positive but have not taken an HIV test and are
unaware of their HIV status—need urgent programme
focus to build awareness of their HIV status and link
them to timely treatment and care. HIV prevention pro-
grammes must intensify efforts to reach all IDUs, focus-
ing on critical sub-groups, including early initiators,
short duration and less frequent injectors, perceived to
be at low risk, to promote regular HIV testing and other
risk reduction behaviours. Providing needles/syringes
alone is not adequate to increase HIV testing; addition-
ally, interventions must focus on providing counselling
services to inform all IDUs about HIV testing benefits,
facilitate visits to testing centres and link HIV-positive
persons to timely treatment and care.
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